Article
IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.
Oncotarget - 9 Feb 2016
de Melo Campos Paula, Machado-Neto João A, Eide Christopher A, Savage Samantha L, Scopim-Ribeiro Renata, da Silva Souza Duarte Adriana, Favaro Patricia, Lorand-Metze Irene, Costa Fernando F, Tognon Cristina E, Druker Brian J, Olalla Saad Sara T, Traina Fabiola
Abstract excerpt
The recurrent V617F mutation in JAK2 (JAK2V617F) has emerged as the primary contributor to the pathogenesis of myeloproliferative neoplasms (MPN). However, the lack of complete response in most patients treated with the JAK1/2 inhibitor, ruxolitinib, indicates the need for identifying pathways that cooperate with JAK2. Activated JAK2 was found to be associated with the insulin receptor substrate 2 (IRS2) in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.